4 No source found (not proven false)
Jimmy Carter was treated with immune checkpoint inhibitors for metastatic melanoma that had spread to his brain, achieving remission.
"One of the big success cases was Jimmy Carter, who had a melanoma, which is a skin cell, aggressive skin cancer that had already gone to his brain, which was thought of as a death sentence. And he got treated with checkpoint inhibitors and basically was cured." (said at 0:53:59)
Former US President Jimmy Carter was widely publicized in 2015 for receiving the immune checkpoint inhibitor pembrolizumab (along with stereotactic radiation and liver surgery) for metastatic melanoma with brain metastases, achieving a durable complete response (remission). However, per the verification protocol for named individual patient cases, no formal peer-reviewed case report published in the biomedical literature indexed in PubMed/Europe PMC was identified documenting his specific clinical records. As a single public patient case / uncontrolled anecdote without an indexed scientific case report, the certainty is very_low.
ArsenalBio is in clinical trials testing CRISPR-engineered T-cell therapies for solid tumors, including prostate cancer.
"We started a company when that technology worked, a company called ArsenalBio that's now in clinical trials. It's actually in its third clinical trial right now for solid tumors. It's in a clinical trial for prostate cancer that's about to start enrolling patients." (said at 1:28:28)
ArsenalBio is a clinical-stage biotechnology company developing non-viral CRISPR-engineered programmable T-cell (CAR-T) therapies for solid tumors, with pipeline candidates including AB-1015 (for ovarian cancer) and AB-2100 (targeting PSMA-positive tumors such as prostate and renal cancers). However, no peer-reviewed journal articles detailing the clinical trial results or enrollment status for these specific ArsenalBio trials were identified in PubMed records at the time of verification. This absence of indexed clinical trial literature does not prove the claim false, as early-phase trials are typically documented in clinical trial registries prior to peer-reviewed publication.
The Gladstone-UCSF Institute of Genomic Immunology is conducting a CRISPR clinical trial for the treatment of multiple myeloma.
"We're actually starting academically in an institute that I run, the Gladstone-UCSF Institute of Genomic Immunology, we're starting a philanthropically funded CRISPR trial for multiple myeloma where we're using a different genetic program." (said at 1:32:00)
No published clinical trial protocol or published trial results describing a philanthropically funded academic CRISPR trial for multiple myeloma led by the Gladstone-UCSF Institute of Genomic Immunology were identified in the searched biomedical databases. While Dr. Alex Marson directs the Gladstone-UCSF Institute of Genomic Immunology and conducts research into CRISPR gene editing in human T cells, specific institutional trial initiatives or newly launching clinical studies often lack formal peer-reviewed publications during their early operational stages. This lack of published peer-reviewed records does not mean the trial does not exist, but renders the specific claim unverified in the medical literature.
Alex Marson's laboratory released a functional genomics dataset mapping the single-cell RNA sequencing profiles of 22 million primary human immune cells with CRISPR gene knockouts.
"We just released 22 million cells where each one has a different CRISPR gene inactivated and we get a map of this" (said at 2:16:20)
No published or indexed peer-reviewed record matching a specific dataset of 22 million primary human immune cells with CRISPR gene knockouts from the Marson laboratory could be verified in the search. While the Marson lab regularly publishes pooled CRISPR perturbation studies and single-cell RNA sequencing datasets in primary human T cells (for example, perturbing 84 transcription factor genes in primary CD4+ T cells; PMID: 39395408), the specific spoken scale of 22 million perturbed single cells may represent a recent pre-print, unpublished repository release, or consortium data release not indexed in standard biomedical literature databases.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.